Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 28 Aug, 01:30 am
Marvell Technology (NASDAQ:MRVL) is set to release its quarterly earnings on August 27, 2026, with analysts projecting $0.93 EPS and $2.72 billion in revenue. The company anticipates significant revenue growth of approximately 35% year-over-year, driven by strong demand in the AI
Positive Analyst Outlook: Canaccord Genuity set a new price target of $175 for Okta, suggesting a potential 30.19% increase from its previous stock price. Consistent Financial Outperformance: Okta reported quarterly earnings of $1.05 per share , surpassing the Zacks Consensus Est
Revolution Medicines (NASDAQ: RVMD) received FDA approval for its groundbreaking pancreatic cancer drug , RASONQUE. Evercore ISI reiterated an "Outperform" rating and significantly raised its price target to $320.00 . RASONQUE's Phase 3 trial demonstrated a 60% reduction in the r
Dollar Tree (NASDAQ: DLTR) reported strong quarterly results, with earnings per share of $2.70 significantly surpassing analyst estimates of $1.15 . The discount retailer's revenue reached $4.89 billion , exceeding expectations and marking a 7.0% increase in total sales. Profitab
Analyst confidence in Veeva Systems is high, with a raised price target suggesting significant upside. The company consistently surpasses financial expectations, reporting strong adjusted earnings per share and revenue growth. Future expansion is fueled by strategic investments i
Agilent Technologies (NYSE: A) reported robust Q3 2026 financial results, significantly beating analyst estimates for both earnings per share and revenue . Citigroup (NYSE: C) reaffirmed its "Buy" rating and raised its price target for Agilent, signaling strong analyst confidence
Despite an " Underperform " rating from Bank of America Securities, HP Inc. (NYSE: HPQ) demonstrated robust financial performance in its fiscal third quarter. The global technology company reported record fiscal third-quarter revenue of $15.7 billion , marking its ninth consecuti
CrowdStrike (NASDAQ: CRWD) reported robust Q2 financial results, surpassing analyst expectations for both earnings per share and revenue. The company demonstrated strong business momentum with a 25% year-over-year increase in Annual Recurring Revenue (ARR) , reaching $5.84 billio
AI Leadership: NVIDIA (NASDAQ: NVDA) maintains its position as a dominant force in the artificial intelligence sector , driven by its critical GPU technology. Optimistic Analyst Outlook: A recent analyst price target hike suggests a significant potential upside for the stock , re
Salesforce (NYSE: CRM) Stock Analysis: Navigating Analyst Ratings, Strong Earnings, and AI Integration Despite an " Underperform " rating from Bernstein, Salesforce demonstrated robust financial performance in its recent earnings report. The company reported strong second-quarter
Mesoblast Limited exceeded quarterly revenue estimates, reporting $69.50 million , and projects strong full-year revenue growth to $120.00 million for fiscal year 2026. Despite revenue performance, the company reported an earnings per share (EPS) of -$0.15 , missing consensus est
Guggenheim Reiterates Buy Rating for Spyre Therapeutics (NASDAQ: SYRE) Amidst Clinical Trial Shifts Leading analyst firm Guggenheim maintains a Buy rating for Spyre Therapeutics despite a recent decline in its biotech stock price. Mixed Phase II clinical trial results for SPY072
Qantas Airways (OTC: QABSY) exceeded analyst expectations with an EPS of $0.89 and a robust underlying profit before tax of A$2.06 billion . The airline's quarterly revenue of $8.90 billion also surpassed estimates, driven by significant growth in international premium cabin reve
Phibro Animal Health (NASDAQ: PAHC) Reports Strong Quarterly Performance and Solid Financials Phibro Animal Health (NASDAQ: PAHC) exceeded analyst expectations with strong earnings per share and revenue growth in its latest quarter. The company's valuation metrics, including a P/
Deutsche Bank Downgrade : Despite a downgrade from Buy to Hold by Deutsche Bank, Regions Financial (NYSE:RF) maintained a stock price of $30.70 . Institutional Investor Confidence : Key institutional investors, including Callan Family Office LLC, Empowered Funds LLC, and Woodline
Hochschild Mining (OTC: HCHDF) reported an impressive 208% increase in earnings per share (EPS) to $0.37 , significantly beating analyst estimates. The precious metals company achieved a 62% year-over-year revenue growth , reaching $844.43 million , driven by higher gold and silv
Oppenheimer has increased its price target for Revolution Medicines (NASDAQ: RVMD) to $260.00 , signaling strong confidence in the biopharmaceutical company. The U.S. Food and Drug Administration (FDA) has approved RASONQUE (daraxonrasib), Revolution Medicines' first broad RAS-ta
Investment Upgrade: Sociedad Química y Minera de Chile (NYSE:SQM) received a "Buy" rating upgrade from Citigroup, indicating a positive market outlook for the Chilean chemical company. Exceptional Financial Performance: The company reported substantial net income and revenue grow
Headlines provided by Investing.com